MedTrace Logo

A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

NCT06581055 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-10-09

No results posted yet for this study

Summary

This study aims to collect real-world data on treatment patterns and clinical outcomes for participants who discontinued Luspatercept or epoetin alfa treatment and discontinued the COMMANDS trial (NCT03682536) utilizing existing data from patient medical records.

Conditions

  • Myelodysplastic Syndromes (MDS)

Interventions

DRUG

Luspatercept

As per COMMANDS Trial (NCT03682536) study protocol

DRUG

Epoetin Alfa

As per COMMANDS Trial (NCT03682536) study protocol

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2025-03-30
Completion
2025-03-30
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06581055 on ClinicalTrials.gov